Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008123 | 1.00 | BTK (0.47) | BTKALOX5APFEN1USP30GPR119 | |
| SCHEMBL16008653 | 1.00 | BTK (0.47) | BTKALOX5APFEN1USP30GPR119 | |
| SCHEMBL18455650 | 0.90 | BTK (0.44) | BTKALOX5APFEN1USP30GPR119 | |
| SCHEMBL16147805 | 0.86 | BTK (0.51) | BTKIRAK4DPP4 | |
| SCHEMBL16008708 | 0.84 | BTK (0.46) | BTKALOX5APFEN1USP30GPR119 | |
| SCHEMBL16008710 | 0.84 | BTK (0.46) | BTKALOX5APFEN1USP30GPR119 | |
| SCHEMBL16007922 | 0.80 | BTK (0.74) | BTKALOX5APFEN1 | |
| SCHEMBL16008832 | 0.80 | BTK (0.74) | BTKALOX5APFEN1 | |
| SCHEMBL16007919 | 0.80 | BTK (0.74) | BTKALOX5APFEN1 | |
| SCHEMBL2539185 | 0.78 | F2RL3 (0.50) | ALOX5APFEN1F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-3235814-B1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9801872-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| EP-3235814-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-2970202-B1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-01 | — | — | EP | disclosed |
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA INC. | 2016-10-27 | — | — | US | disclosed |
| US-9402841-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| EP-2970202-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164558-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-09 | — | — | WO | disclosed |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310483-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | BTK 1/4885ALOX5AP 1982/4885FEN1 1375/4885 |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | BTK 1/4885ALOX5AP 1982/4885FEN1 1375/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | BTK 1/4885ALOX5AP 1982/4885FEN1 1375/4885 |
| US-20140256734-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | BTK 1/4885ALOX5AP 1982/4885FEN1 1375/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | BTK 1/4885ALOX5AP 1982/4885FEN1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.